Publications by authors named "Carl Whatling"

Claim this Profile
A
A Phase 2a Trial of Myeloperoxidase Inhibitor Mitiperstat in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis.
Javier Armisen, Armando Flor, John Eriksson, Karin Nelander, Chandrali S Bhattacharya, Carl Whatling

Liver Int· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Tolerability, and Pharmacodynamics of AZD3366 (Optimized Human CD39L3 Apyrase) Alone and in Combination With Ticagrelor and Acetylsalicylic Acid: A Phase 1, Randomized, Placebo-Controlled Study.
Dimitris Kardassis, Ann-Charlotte Egnell, Magnus Åstrand, Samuel J Daniels, Carl Whatling

J Am Heart Assoc· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rationale and design of ENDEAVOR: A sequential phase 2b-3 randomized clinical trial to evaluate the effect of myeloperoxidase inhibition on symptoms and exercise capacity in heart failure with preserved or mildly reduced ejection fraction.
Lars H Lund, Carolyn S P Lam, Patricia E Pizzato, Anders Gabrielsen, Erik Michaëlsson, Carl Whatling

Eur J Heart Fail· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recombinant Apyrase (AZD3366) Against Myocardial Reperfusion Injury.
Yochai Birnbaum, Regina Ye, Huan Chen, Leif Carlsson, Carl Whatling

Cardiovasc Drugs Ther· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of genetic variations with NAFLD in lean individuals.
Huapeng Lin, Grace L-H Wong, Carl Whatling, Anthony W-H Chan, Howard H-W Leung

Liver Int· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A mechanistic framework for cardiometabolic and coronary artery diseases.
Simon Koplev, Marcus Seldin, Katyayani Sukhavasi, Raili Ermel, Shichao Pang, Carl Whatling

Nat Cardiovasc Res· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design of FLAIR: a Phase 2b Study of the 5-Lipoxygenase Activating Protein Inhibitor AZD5718 in Patients With Proteinuric CKD.
Hiddo J L Heerspink, Gordon Law, Konstantina Psachoulia, Kathleen Connolly, Carl Whatling

Kidney Int Rep· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, Pharmacodynamics, and Tolerability of AZD5718, an Oral 5-Lipoxygenase-Activating Protein (FLAP) Inhibitor, in Healthy Japanese Male Subjects.
Jane Knöchel, Karin Nelander, Maria Heijer, Eva-Lotte Lindstedt, Gun-Britt Forsberg, Carl Whatling

Clin Drug Investig· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early Clinical Experience With AZD4831, A Novel Myeloperoxidase Inhibitor, Developed for Patients With Heart Failure With Preserved Ejection Fraction.
Karin Nelander, Maria Lagerstrom-Fermer, Carl Amilon, Erik Michaëlsson, Maria Heijer, Carl Whatling

Clin Transl Sci· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel Lesional Transcriptional Signature Separates Atherosclerosis With and Without Diabetes in Yorkshire Swine and Humans.
Stefan Haemmig, Ali Hashemi Gheinani, Marina Zaromytidou, Gerasimos Siasos, Ahmet Umit Coskun, Carl Whatling

Arterioscler Thromb Vasc Biol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diastolic dysfunction and impaired cardiac output reserve in dysmetabolic nonhuman primate with proteinuria.
Johannes Wikstrom, Yongqiang Liu, Carl Whatling, Li-Ming Gan, Peter Konings

J Diabetes Complications· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An integrative multiomic network model links lipid metabolism to glucose regulation in coronary artery disease.
Ariella T Cohain, William T Barrington, Daniel M Jordan, Noam D Beckmann, Carmen A Argmann, Carl Whatling

Nat Commun· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a highly sensitive liquid chromatography-mass spectrometry method to quantify plasma leukotriene E and demonstrate pharmacological suppression of endogenous 5-LO pathway activity in man.
Lars Löfgren, Gun-Britt Forsberg, Pia Davidsson, Susanna Eketjäll, Carl Whatling

Prostaglandins Other Lipid Mediat· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The TM6SF2 E167K genetic variant induces lipid biosynthesis and reduces apolipoprotein B secretion in human hepatic 3D spheroids.
Sebastian Prill, Andrea Caddeo, Guido Baselli, Oveis Jamialahmadi, Paola Dongiovanni, Carl Whatling

Sci Rep· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Highly sensitive and specific LC-MS/MS method to determine endogenous leukotriene B4 levels in human plasma.
Maria Bhat, Anna Lindgren, Susanna Eketjäll, Rabia Hidi, Philipp Schatz, Carl Whatling

Bioanalysis· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and Early Clinical Development of an Inhibitor of 5-Lipoxygenase Activating Protein (AZD5718) for Treatment of Coronary Artery Disease.
Daniel Pettersen, Johan Broddefalk, Hans Emtenäs, Martin A Hayes, Malin Lemurell, Carl Whatling

J Med Chem· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel Chemical Series of 5-Lipoxygenase-Activating Protein Inhibitors for Treatment of Coronary Artery Disease.
Malin Lemurell, Johan Ulander, Hans Emtenäs, Susanne Winiwarter, Johan Broddefalk, Carl Whatling

J Med Chem· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability, pharmacokinetics and effect on serum uric acid of the myeloperoxidase inhibitor AZD4831 in a randomized, placebo-controlled, phase I study in healthy volunteers.
Li-Ming Gan, Maria Lagerström-Fermér, Hans Ericsson, Karin Nelander, Eva-Lotte Lindstedt, Carl Whatling

Br J Clin Pharmacol· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Initial Clinical Experience with AZD5718, a Novel Once Daily Oral 5-Lipoxygenase Activating Protein Inhibitor.
Hans Ericsson, Karin Nelander, Maria Lagerstrom-Fermer, Clare Balendran, Maria Bhat, Carl Whatling

Clin Transl Sci· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Myeloperoxidase Levels and Its Product 3-Chlorotyrosine Predict Chronic Kidney Disease Severity and Associated Coronary Artery Disease.
Farsad Afshinnia, Lixia Zeng, Jaeman Byun, Crystal A Gadegbeku, Maria Chiara Magnone, Carl Whatling

Am J Nephrol· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Ticagrelor Removal From Human Blood.
George O Angheloiu, Gabriel B Gugiu, Cristian Ruse, Rishikesh Pandey, Ramachandra R Dasari, Carl Whatling

JACC Basic Transl Sci· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Ticagrelor regulates osteoblast and osteoclast function and promotes bone formation in vivo via an adenosine-dependent mechanism.
Aránzazu Mediero, Tuere Wilder, Vishnu S R Reddy, Qian Cheng, Nick Tovar, Carl Whatling

FASEB J· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply.
Sandrine Delbosc, Carl Whatling, Jean-Baptiste Michel

J Vasc Surg· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recent advances for FLAP inhibitors.
Daniel Pettersen, Öjvind Davidsson, Carl Whatling

Bioorg Med Chem Lett· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of AZD6642, an inhibitor of 5-lipoxygenase activating protein (FLAP) for the treatment of inflammatory diseases.
Malin Lemurell, Johan Ulander, Susanne Winiwarter, Anders Dahlén, Öjvind Davidsson, Carl Whatling

J Med Chem· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis